Latest Intelligence on Pharmaceuticals and Healthcare in Canada

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Sanofi-Aventis/Apotex: olive branch acceptance to reduce generic threat

Sanofi-Aventis and Bristol-Myers Squibb have reached an agreement to settle a patent infringement suit with Canadian generics maker Apotex over the anti-platelet agent Plavix. As well as enabling the companies to avoid court proceedings, the settlement should delay the generic threat to Plavix - a possibility the pharma heavyweights' investors have already embraced judging by share price surges.

Published By Datamonitor
23 Mar 2006
CommentWire
CommentWire

Transition Therapeutics: showing potential in hepatitis

Toronto-based Transition Therapeutics has posted positive 12-week data from a phase I/II trial investigating the safety and efficacy of HCV-IET in hepatitis C non-responders. However, although its results to date look promising, the drug candidate looks set to face stiff competition from other pipeline products, several of which appear to have a head-start.

Published By Datamonitor
08 Aug 2006
CommentWire
CommentWire

Neurochem: promising results for next generation Alzheimer's drug

Phase II trial results for Alzhemed (tramiprosate) demonstrate efficacy in mild Alzheimer's disease patients while being both safe and well tolerated. Considering current treatment offers only a modest improvement in symptoms, Alzhemed represents a potentially exciting disease-modifying approach and could potentially pose a substantial threat to current market leaders.

Published By Datamonitor
03 Nov 2006
CommentWire
CommentWire

Neurochem: excitement builds as Alzhemed phase III trial is completed

Neurochem has completed a North American phase III clinical trial for Alzhemed for the treatment of Alzheimer's disease. If approved, the drug will be the first disease modifying drug in this area to reach the market and will therefore represent a crucial step forward in the treatment of the disease. Alzhemed is anticipated to be largely used in combination with currently marketed drugs.

Published By Datamonitor
02 Feb 2007
CommentWire
CommentWire

BioMS Medical: potential to broaden MS treatment options

BioMS has initiated an open-label extension of its MAESTRO-01 pivotal phase II/III trial of MBP-8298 in patients with secondary progressive multiple sclerosis. MBP-8298 has the potential to broaden the currently narrow treatment options for this form of MS as well as offering an improved dosing regimen.

Published By Datamonitor
02 Mar 2007
CommentWire
CommentWire

Ambrilia: peptide therapy shows early promise

Ambrilia's investigational drug PCK3145 has shown preliminary signs of anti-tumor activity for sufferers of metastatic prostate cancer in a phase I/II clinical trial. While there is considerable unmet need in this therapy area, the development and commercialization of PCK3145 will be challenged by competing pipeline and marketed drugs.

Published By Datamonitor
25 Apr 2007
CommentWire
CommentWire

Janssen-Cilag: Stelara set to shine for psoriasis

Janssen-Cilag's Stelara has received European approval for the treatment of moderate to severe plaque psoriasis in adults refractory or intolerant to other systemic therapies. Having now been approved in both Canada and the EU, Stelara stands to command significant market share if it is approved in the US and fulfils physicians' expectations.

Published By Datamonitor
23 Jan 2009
CommentWire
CommentWire

Nycomed/Merck: Daxas deal will have limited financial impact

Nycomed and Merck & Co. have agreed to co-promote the novel COPD therapy Daxas, which recently gained a positive recommendation in the EU. While this collaboration boosts Daxas' commercial prospects in several European countries, as well as Canada, the drug is limited by its restricted patient potential.

Published By Datamonitor
28 Apr 2010
CommentWire
CommentWire

Johnson & Johnson: Remicade gains another indication

Pediatric patients in Canada will become the first to have access to Remicade for treating moderately to severely active ulcerative colitis, following Health Canada's approval of the drug for this indication. The regulator's decision is likely to pave the way for similar indication extensions for children in other markets.

Published By Datamonitor
05 Sep 2011

« | 1 | 2 | 3 | 4 | » »|

No help is available.